Skip to content

Similar metrics at other companies

Liberty Global logo
LBTYBOther — 2028
$0
Liberty Global logo
LBTYBOther — 2026
$23.4M-92.4%
Liberty Global logo
LBTYBOther — 2029
$0
Cabot Corporation logo
CBTOther — Recorded Unconditional Purchase Obligation Due In Second Year
$9M
Cabot Corporation logo
CBTOther — Recorded Unconditional Purchase Obligation Due In Third Year
$4M
Cabot Corporation logo
CBTOther — Recorded Unconditional Purchase Obligation Due In Fourth Year
$2M

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$958.91M-14.5%
Enterprise value$1.23B+2.6%
P/E186.6×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PurchaseObligationDueInThirdYear.

The official record: Pacira BioSciences, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s other — due 2028.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s other — due 2028?
Pacira BioSciences, Inc. (PCRX) reported other — due 2028 of $700K in Q4 2025.
What does other — due 2028 mean?
Represents the portion of contractual purchase obligations within the 'Other' business segment that are scheduled for payment during the fiscal year 2028. By isolating obligations due in this specific period, investors can better forecast the company's long-term financial health and capital allocation strategy. This metric highlights the extent of fixed costs the company has locked in for the medium term.